1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Pneumonia Therapeutics Market
2.3. Global Pneumonia Therapeutics Market, By Infection Type, 2025 (US$ Million)
2.4. Global Pneumonia Therapeutics Market, By Treatment Type, 2025 (US$ Million)
2.5. Global Pneumonia Therapeutics Market, By Age Group, 2025 (US$ Million)
2.6. Global Pneumonia Therapeutics Market, By Route of Administration, 2025 (US$ Million)
2.7. Global Pneumonia Therapeutics Market, By End Use, 2025 (US$ Million)
2.8. Global Pneumonia Therapeutics Market, By Geography, 2025 (US$ Million)
2.9. Attractive Investment Proposition by Geography, 2025

3. Pneumonia Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Pneumonia Therapeutics Market Vendors
3.2. Strategies Adopted by Pneumonia Therapeutics Market Vendors

4. Pneumonia Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Pneumonia Therapeutics Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Community-acquired pneumonia (CAP)
5.3.2. Hospital-acquired pneumonia (HAP)
5.3.3. Ventilator-associated pneumonia (VAP)
5.3.4. Other infection types

6. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Drug class
6.3.1.1. Antibacterial drugs Quinolones Macrolide Other antibacterial drugs
6.3.1.2. Quinolones
6.3.1.3. Macrolide
6.3.1.4. Other antibacterial drugs
6.3.1.5. Antiviral drugs
6.3.1.6. Antifungal drugs
6.3.1.7. Other drug classes
6.3.2. Vaccines
6.3.3. Oxygen therapy

7. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2025 Versus 2034
7.3. Market Segmentation
7.3.1. Pediatrics
7.3.2. Adults
7.3.3. Geriatrics

8. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2025 Versus 2034
8.3. Market Segmentation
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Other routes of administration

9. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Growth & Revenue Analysis: 2025 Versus 2034
9.3. Market Segmentation
9.3.1. Hospitals and clinics
9.3.2. Homecare settings
9.3.3. Other end use

10. North America Pneumonia Therapeutics Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
10.3. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
10.4. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
10.5. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
10.7. Pneumonia Therapeutics Market: By Region, 2024-2034, USD (Million)
10.7.1.North America
10.7.1.1. U.S.
10.7.1.1.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
10.7.1.1.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
10.7.1.1.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
10.7.1.1.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.7.1.1.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
10.7.1.2. Canada
10.7.1.2.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
10.7.1.2.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
10.7.1.2.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
10.7.1.2.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.7.1.2.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
10.7.1.3. Rest of North America
10.7.1.3.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
10.7.1.3.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
10.7.1.3.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
10.7.1.3.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.7.1.3.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)

11. UK and European Union Pneumonia Therapeutics Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.3. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.4. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.5. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
11.7. Pneumonia Therapeutics Market: By Region, 2024-2034, USD (Million)
11.7.1.UK and European Union
11.7.1.1. UK
11.7.1.1.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.7.1.1.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.7.1.1.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.7.1.1.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.7.1.1.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
11.7.1.2. Germany
11.7.1.2.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.7.1.2.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.7.1.2.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.7.1.2.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.7.1.2.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
11.7.1.3. Spain
11.7.1.3.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.7.1.3.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.7.1.3.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.7.1.3.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.7.1.3.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
11.7.1.4. Italy
11.7.1.4.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.7.1.4.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.7.1.4.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.7.1.4.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.7.1.4.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
11.7.1.5. France
11.7.1.5.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.7.1.5.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.7.1.5.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.7.1.5.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.7.1.5.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
11.7.1.6. Rest of Europe
11.7.1.6.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
11.7.1.6.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
11.7.1.6.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
11.7.1.6.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.7.1.6.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)

12. Asia Pacific Pneumonia Therapeutics Market, 2024-2034, USD (Million)
12.1. Market Overview
12.2. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.3. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.4. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.5. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.6. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
12.7. Pneumonia Therapeutics Market: By Region, 2024-2034, USD (Million)
12.7.1.Asia Pacific
12.7.1.1. China
12.7.1.1.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.7.1.1.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.7.1.1.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.7.1.1.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.7.1.1.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
12.7.1.2. Japan
12.7.1.2.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.7.1.2.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.7.1.2.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.7.1.2.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.7.1.2.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
12.7.1.3. India
12.7.1.3.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.7.1.3.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.7.1.3.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.7.1.3.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.7.1.3.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
12.7.1.4. Australia
12.7.1.4.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.7.1.4.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.7.1.4.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.7.1.4.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.7.1.4.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
12.7.1.5. South Korea
12.7.1.5.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.7.1.5.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.7.1.5.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.7.1.5.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.7.1.5.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
12.7.1.6. Rest of Asia Pacific
12.7.1.6.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
12.7.1.6.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
12.7.1.6.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
12.7.1.6.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.7.1.6.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)

13. Latin America Pneumonia Therapeutics Market, 2024-2034, USD (Million)
13.1. Market Overview
13.2. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
13.3. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
13.4. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
13.5. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.6. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
13.7. Pneumonia Therapeutics Market: By Region, 2024-2034, USD (Million)
13.7.1.Latin America
13.7.1.1. Brazil
13.7.1.1.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
13.7.1.1.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
13.7.1.1.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
13.7.1.1.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.7.1.1.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
13.7.1.2. Mexico
13.7.1.2.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
13.7.1.2.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
13.7.1.2.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
13.7.1.2.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.7.1.2.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
13.7.1.3. Rest of Latin America
13.7.1.3.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
13.7.1.3.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
13.7.1.3.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
13.7.1.3.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.7.1.3.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)

14. Middle East and Africa Pneumonia Therapeutics Market, 2024-2034, USD (Million)
14.1. Market Overview
14.2. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
14.3. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
14.4. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
14.5. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
14.6. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
14.7. Pneumonia Therapeutics Market: By Region, 2024-2034, USD (Million)
14.7.1.Middle East and Africa
14.7.1.1. GCC
14.7.1.1.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
14.7.1.1.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
14.7.1.1.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
14.7.1.1.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
14.7.1.1.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
14.7.1.2. Africa
14.7.1.2.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
14.7.1.2.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
14.7.1.2.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
14.7.1.2.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
14.7.1.2.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)
14.7.1.3. Rest of Middle East and Africa
14.7.1.3.1. Pneumonia Therapeutics Market: By Infection Type, 2024-2034, USD (Million)
14.7.1.3.2. Pneumonia Therapeutics Market: By Treatment Type, 2024-2034, USD (Million)
14.7.1.3.3. Pneumonia Therapeutics Market: By Age Group, 2024-2034, USD (Million)
14.7.1.3.4. Pneumonia Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
14.7.1.3.5. Pneumonia Therapeutics Market: By End Use, 2024-2034, USD (Million)

15. Company Profile
15.1. Abbott Laboratories (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
15.2. AbbVie
15.3. AstraZeneca
15.4. Baxter International
15.5. Bayer
15.6. Bristol Myers Squibb
15.7. Cipla
15.8. Daiichi Sankyo
15.9. F. Hoffmann-La Roche
15.10. GlaxoSmithKline
15.11. Johnson & Johnson
15.12. Lupin Pharmaceuticals
15.13. Merck & Co.
15.14. Mylan
15.15. Novartis
15.16. Pfizer
15.17. Teva Pharmaceuticals
15.18. Other Notable Players